Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon α

Chronic myeloid leukemia (CML) in older patients has not been studied well. To assess the long-term outcome of older patients with Philadelphia- and/or BCR-ABL-positive CML, 199 patients aged ⩾60 years representing 23% of 856 patients enrolled in the German randomized CML-studies I (interferon α (IF...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2003-09, Vol.17 (9), p.1820-1826
Hauptverfasser:	Berger, U, Engelich, G, Maywald, O, Pfirrmann, M, Hochhaus, A, Reiter, A, Metzgeroth, G, Gnad, U, Hasford, J, Heinze, B, Heimpel, H, Hossfeld, D K, Kolb, H-J, Löffler, H, Pralle, H, Queisser, W, Hehlmann, R
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use BCR-ABL protein Biological and medical sciences Busulfan Busulfan - therapeutic use Cancer Research Chemotherapy Child Chronic myeloid leukemia Clinical trials Critical Care Medicine Cytogenetics Diagnosis Diseases Dosage and administration Drug therapy Female Follow-Up Studies Fusion protein Fusion Proteins, bcr-abl Hematologic and hematopoietic diseases Hematology Humans Hydroxyurea Hydroxyurea - therapeutic use Intensive Interferon Interferon alpha Interferon-alpha - therapeutic use Internal Medicine Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Leukocyte Count Male Medical examination Medical sciences Medicine Medicine & Public Health Middle Aged Myeloid leukemia Older people Oncology original-manuscript Patients Prognosis Protein-Tyrosine Kinases - metabolism Randomized Controlled Trials as Topic Risk Survival Survival Rate Toxicity Treatment Outcome α-Interferon
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!